• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cytek Biosciences Inc.

    2/27/26 4:30:36 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $CTKB alert in real time by email
    S-8 1 d106864ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 27, 2026

    Registration No. 333- 

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Cytek Biosciences, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   47-2547526

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    47215 Lakeview Boulevard

    Fremont, California 94538

    (Address of Principal Executive Offices) (Zip Code)

    Cytek Biosciences, Inc. 2021 Equity Incentive Plan

    Cytek Biosciences, Inc. 2021 Employee Stock Purchase Plan

    (Full title of the plans)

    Wenbin Jiang, Ph.D.

    President and Chief Executive Officer

    Cytek Biosciences, Inc.

    47215 Lakeview Boulevard

    Fremont, California 94538

    (877) 922-9835

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Please send copies of all communications to:

     

    Gordon K. Ho

    Cooley LLP

    3175 Hanover Street

    Palo Alto, California 94304

    (650) 843-5000

     

    Valerie Barnett

    Chief Legal Officer

    Cytek Biosciences, Inc.

    47215 Lakeview Boulevard

    Fremont, California 94538

    (877) 922-9835

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☒
    Non-accelerated filer   ☐    Smaller reporting company   ☐
    Emerging growth company   ☐     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E

    Pursuant to General Instruction E of Form S-8, Cytek Biosciences, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) to register 5,142,005 additional shares of common stock under the Registrant’s 2021 Equity Incentive Plan and 1,285,501 additional shares of common stock under the Registrant’s 2021 Employee Stock Purchase Plan pursuant to the provisions of those plans providing for an automatic increase in the number of shares reserved for issuance under such plans on January 1 of each year pursuant to a specified formula. This Registration Statement hereby incorporates by reference the contents of the Registrant’s prior registration statements on Form S-8 filed with the Commission on February  28, 2025 (Registration No. 333-285446), March  14, 2024 (Registration No. 333-277936), March  2, 2023 (Registration No. 333-270200), March  17, 2022 (Registration No. 333-263661) and  July 23, 2021 (Registration No. 333-258153).

    PART II

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

    The following documents filed by Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on February 26, 2026; and

    (b) The description of the Registrant’s Common Stock contained in the registration statement on Form  8-A registering the Registrant’s Common Stock under Section 12 of the Exchange Act filed with the Commission on July 19, 2021, including any amendments or reports filed for purposes of updating such description.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    II-2


    ITEM 8. EXHIBITS.

    The following exhibits are filed herewith:

     

             

    Incorporated by Reference

    Exhibit

    Number

      

    Exhibit Description

      

    Form

      

    File No.

      

    Exhibit

      

    Filing Date

      

    Filed Herewith

    4.1    Amended and Restated Certificate of Incorporation of Cytek Biosciences, Inc.    8-K    001-40632    3.1    7/27/2021   
    4.2    Amended and Restated Bylaws of Cytek Biosciences, Inc.    8-K    001-40632    3.2    7/27/2021   
    4.3    Form of common stock certificate of Cytek Biosciences, Inc.    S-1/A    333-257663    4.1    7/19/2021   
    5.1    Opinion of Cooley LLP                X
    23.1    Consent of Cooley LLP (included in Exhibit 5.1)                X
    23.2    Consent of Independent Registered Public Accounting Firm                X
    24.1    Power of Attorney (included on the signature page of this Registration Statement)                X
    99.1    Cytek Biosciences, Inc. 2021 Equity Incentive Plan    S-1/A    333-257663    10.4    7/19/2021   
    99.2    Forms of Option Agreement and Notice of Stock Option Grant under 2021 Equity Incentive Plan    S-1/A    333-257663    10.5    7/19/2021   
    99.3    Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan    10-Q    001-40632    10.2    11/12/2021   
    99.4    Forms of Option Agreement and Notice of Stock Option Grant under 2021 Equity Incentive Plan, effective August 23, 2022.    10-Q    001-40632    10.1    11/09/2022   
    99.5    Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan, effective August 23, 2022.    10-Q    001-40632    10.2    11/09/2022   
    99.6    Cytek Biosciences, Inc. 2021 Employee Stock Purchase Plan    S-1/A    333-257663    10.6    7/19/2021   
    107    Filing Fee Table                X

     

    II-3


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California, on February 27, 2026.

     

    CYTEK BIOSCIENCES, INC.

    /s/ Wenbin Jiang, Ph.D.

    Wenbin Jiang, Ph.D.
    President and Chief Executive Officer

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Wenbin Jiang, William McCombe and Valerie Barnett, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated:

     

    Name

      

    Title

      

    Date

    /s/ Wenbin Jiang, Ph.D.

       President, Chief Executive Officer and Director    February 27, 2026
    Wenbin Jiang, Ph.D.    (Principal Executive Officer)   

    /s/ William McCombe

       Chief Financial Officer    February 27, 2026
    William McCombe    (Principal Financial and Accounting Officer)   

    /s/ Ming Yan, Ph.D.

       Chief Technology Officer and Director    February 27, 2026
    Ming Yan, Ph.D.      

    /s/ Jack Ball

       Director    February 27, 2026
    Jack Ball      

    /s/ Richard Chin, M.D.

       Director    February 27, 2026
    Richard Chin, M.D.      

    /s/ Michael Holder

       Director    February 27, 2026
    Michael Holder      

    /s/ Vera Imper, Ph.D.

       Director    February 27, 2026
    Vera Imper, Ph.D.      

    /s/ Deborah Neff

       Director    February 27, 2026
    Deborah Neff      

     

    II-4

    Get the next $CTKB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTKB

    DatePrice TargetRatingAnalyst
    12/2/2025$6.00Equal-Weight
    Morgan Stanley
    5/9/2025$4.00Buy → Hold
    TD Cowen
    1/31/2025$7.00 → $4.50Buy → Sell
    Goldman
    12/14/2023$9.00Overweight
    Stephens
    7/19/2023Mkt Perform
    Raymond James
    2/15/2022$27.00 → $18.00Equal-Weight
    Morgan Stanley
    1/6/2022$20.00Overweight
    Piper Sandler
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $CTKB
    SEC Filings

    View All

    SEC Form 8-K filed by Cytek Biosciences Inc.

    8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

    6/2/26 4:15:52 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SD filed by Cytek Biosciences Inc.

    SD - Cytek Biosciences, Inc. (0001831915) (Filer)

    6/1/26 4:07:56 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.

    SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

    5/18/26 6:22:44 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026

    FREMONT, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- At CYTO 2026, the industry's premier flow cytometry conference, spectral flow cytometry leader Cytek Biosciences, Inc. (NASDAQ:CTKB) will showcase its expanding portfolio of end-to-end cell analysis solutions, including the public debut of a new 7-laser Cytek Borealis full spectrum flow cytometer, as well as automation-ready configurations of the Cytek Aurora Evo system. The 39th annual Congress, themed Cytometry: The Next Wave, will spotlight emerging technologies shaping the future of the field. Cytek continues to play a central role in that evolution, advancing high-parameter analysis through innovations designed to increase flexibilit

    6/2/26 5:00:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences Reports First Quarter 2026 Financial Results

    FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Total revenue for the first quarter of 2026 was $44.1 million, representing a 6% increase compared to the first quarter of 2025Service revenue for the first quarter of 2026 was $15.4 million, representing a 15% increase compared to the first quarter of 2025Total recurring revenue, comprised of service and reagent revenues, reached $18.4 million in the first quarter. On a trailing-12-month basis, recurring revenue represented 35% of

    5/7/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Leadership Updates

    Live Leadership Updates

    View All

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

    IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

    7/3/25 1:00:00 PM ET
    $CTKB
    $MDXH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    Cytek Announces Resignation of Chief Operating Officer Chris Williams

    FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef

    9/12/24 3:20:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Holder Michael converted options into 1,454 shares, increasing direct ownership by 10% to 16,721 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    5/20/26 6:01:31 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Chin Richard converted options into 6,107 shares, increasing direct ownership by 38% to 22,392 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    5/20/26 5:59:27 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CHIEF TECHNOLOGY OFFICER Yan Ming converted options into 22,179 shares and covered exercise/tax liability with 5,532 shares, increasing direct ownership by 0.34% to 4,932,580 units (SEC Form 4) (tax withholding)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    5/20/26 5:56:22 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Cytek Biosciences with a new price target

    Morgan Stanley resumed coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $6.00

    12/2/25 8:24:49 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences downgraded by TD Cowen with a new price target

    TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00

    5/9/25 8:41:00 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences downgraded by Goldman with a new price target

    Goldman downgraded Cytek Biosciences from Buy to Sell and set a new price target of $4.50 from $7.00 previously

    1/31/25 6:59:30 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mccombe William D. bought $97,300 worth of shares (35,000 units at $2.78), increasing direct ownership by 169% to 55,746 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    6/3/25 5:39:17 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 4:35:51 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

    SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 1:42:15 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    2/22/24 7:07:27 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Financials

    Live finance-specific insights

    View All

    Cytek Biosciences Reports First Quarter 2026 Financial Results

    FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Total revenue for the first quarter of 2026 was $44.1 million, representing a 6% increase compared to the first quarter of 2025Service revenue for the first quarter of 2026 was $15.4 million, representing a 15% increase compared to the first quarter of 2025Total recurring revenue, comprised of service and reagent revenues, reached $18.4 million in the first quarter. On a trailing-12-month basis, recurring revenue represented 35% of

    5/7/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

    FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced that it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generation

    4/23/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

    FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 2025 was $201.5 million, a 1% increase compared to the full year 2024Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of

    2/26/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials